Protective Effects of SGLT2 Inhibitor Luseogliflozin on Pancreatic Beta Cells in Obese Diabetic db/db Mice-"The Earlier and Longer, the Better"

被引：0
|
作者：
Kimura, Tomohiko
Shimoda, Masashi
Nakanishi, Shuhei
Mune, Tomoatsu
Kaku, Kohei
Kaneto, Hideaki
机构：
来源：
DIABETES | 2018年 / 67卷
关键词：
D O I：
10.2337/db18-2111-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Protective effects of the SGLT2 inhibitor luseogliflozin on pancreatic β-cells in db/db mice: The earlier and longer, the better
    Kimura, Tomohiko
    Obata, Atsushi
    Shimoda, Masashi
    Okauchi, Seizo
    Kanda-Kimura, Yukiko
    Nogami, Yuka
    Moriuchi, Saeko
    Hirukawa, Hidenori
    Kohara, Kenji
    Nakanishi, Shuhei
    Mune, Tomoatsu
    Kaku, Kohei
    Kaneto, Hideaki
    DIABETES OBESITY & METABOLISM, 2018, 20 (10): : 2442 - 2457
  • [2] Protective Effects of SGLT2 Inhibitor Luseogliflozin on Pancreatic Beta Cells in Obese Type 2 Diabetic db/db Mice
    Okauchi, Seizou
    Simoda, Masashi
    Obata, Atsushi
    Kimura, Tomohiko
    Hirukawa, Hidenori
    Kohara, Kenji
    Kaneto, Hideaki
    Kaku, Kohei
    DIABETES, 2015, 64 : A586 - A586
  • [3] Protective effects of SGLT2 inhibitor luseogliflozin on pancreatic β-cells in obese type 2 diabetic db/db mice
    Okauchi, Seizo
    Shimoda, Masashi
    Obata, Atsushi
    Kimura, Tomohiko
    Hirukawa, Hidenori
    Kohara, Kenji
    Mune, Tomoatsu
    Kaku, Kohei
    Kaneto, Hideaki
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2016, 470 (03) : 772 - 782
  • [4] Luseogliflozin (TS-071), a novel SGLT2 inhibitor, protects against diabetic nephropathy in diabetic db/db mice
    Takiyama, Y.
    Agatsuma, K.
    Yasuda-Kobayashi, M.
    Honjo, J.
    Fujita, Y.
    Yanagimachi, T.
    Kitsunai, H.
    Makino, Y.
    Haneda, M.
    DIABETOLOGIA, 2013, 56 : S66 - S66
  • [5] Extracellular lipidome change by an SGLT2 inhibitor, luseogliflozin, contributes to prevent skeletal muscle atrophy in db/db mice
    Bamba, Ryo
    Okamura, Takuro
    Hashimoto, Yoshitaka
    Majima, Saori
    Senmaru, Takafumi
    Ushigome, Emi
    Nakanishi, Naoko
    Asano, Mai
    Yamazaki, Masahiro
    Takakuwa, Hiroshi
    Hamaguchi, Masahide
    Fukui, Michiaki
    JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE, 2022, 13 (01) : 574 - 588
  • [6] Protective Effect of Ipragliflozin on Pancreatic Islet Cells in Obese Type 2 Diabetic db/db Mice
    Takasu, Toshiyuki
    Takakura, Shoji
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2018, 41 (05) : 761 - 769
  • [7] Gut Microbiota Changes by an SGLT2 Inhibitor, Luseogliflozin, Alters Metabolites Compared with Those in a Low Carbohydrate Diet in db/db Mice
    Hata, Shinnosuke
    Okamura, Takuro
    Kobayashi, Ayaka
    Bamba, Ryo
    Miyoshi, Tomoki
    Nakajima, Hanako
    Kitagawa, Nobuko
    Hashimoto, Yoshitaka
    Majima, Saori
    Senmaru, Takafumi
    Okada, Hiroshi
    Ushigome, Emi
    Nakanishi, Naoko
    Takakuwa, Hiroshi
    Sasano, Ryoichi
    Hamaguchi, Masahide
    Fukui, Michiaki
    NUTRIENTS, 2022, 14 (17)
  • [8] Nephropathy in diabetic db/db mice is accelerated by high protein diet and improved by the SGLT2 inhibitor dapagliflozin
    Norgaard, Sisse Andersen
    Briand, Francois
    Sand, Fredrik Wolfhagen
    Galsgaard, Elisabeth Douglas
    Sondergaard, Henrik
    Sorensen, Dorte Bratbo
    Sulpice, Thierry
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2019, 860
  • [9] Effect of the sodium–glucose cotransporter 2 inhibitor luseogliflozin on pancreatic beta cell mass in db/db mice of different ages
    Kiyohiko Takahashi
    Akinobu Nakamura
    Hideaki Miyoshi
    Hiroshi Nomoto
    Naoyuki Kitao
    Kazuno Omori
    Kohei Yamamoto
    Kyu Yong Cho
    Yasuo Terauchi
    Tatsuya Atsumi
    Scientific Reports, 8
  • [10] Effects of Combining Linagliptin Treatment with BI-38335, A Novel SGLT2 Inhibitor, on Pancreatic Islet Function and Inflammation in db/db Mice
    Chen, L.
    Klein, T.
    Leung, P. S.
    CURRENT MOLECULAR MEDICINE, 2012, 12 (08) : 995 - 1004
12345